Natalizumab and PML: a risky business?

Clifford, David B.
October 2008
Gut;Oct2008, Vol. 57 Issue 10, p1347
Academic Journal
The article discusses the development of treatments including natalizumab (Tysabri), a drug used to treat Crohn's disease. It cites that the drug is a humanized monoclonal antibody against 4-integrin, which is first approved for treatment on relapsing multiple sclerosis (MS). It contends that this drug minimizes the activity of MS as shown by the development of magnetic resonance (MR) brain lesions and slowing progression of disability.


Related Articles

  • Natalizumab for moderateto- severe Crohn disease.  // WHO Drug Information;2008, Vol. 22 Issue 1, p20 

    The article reports on the approval of natalizumab antibodies in treating multiple sclerosis and moderate-to-severe Crohn disease by the Food and Drug Administration (FDA) in the U.S. FDA proves that natalizumab is an effective agent in treating Crohn disease in patients with evidence of...

  • First-time generic approval.  // Formulary;Feb2008, Vol. 43 Issue 2, p42 

    The article discusses the approval of natalizumab, a drug marketed as Tysabri, for the treatment of moderate-to-severe Crohn's disease (CD). The drug was approved on January 14, 2008, after positive results were indicated in the three randomized, double-blind controlled trials being conducted to...

  • The present efficacy of multiple sclerosis therapeutics: is the new 66% just the old 33%?  // Current Medical Literature: Multiple Sclerosis;2010, Vol. 1 Issue 4, p96 

    The article discusses a study by E. C. Klawiter and colleagues on the efficacy of monoclonal antibodies, specifically natalizumab, interferon beta, and glatiramer ecetate in the management of patients with multiple sclerosis (MS).

  • Balancing the risks and benefits of prolonged use of infliximab. Schölmerich, Jürgen // Gut;Apr2009, Vol. 58 Issue 4, p477 

    In this article, the author discusses the result of a study conducted in Leuven, Belgium to determine the efficacy on the use of infliximab in Crohn's disease. The result of the study shows that 614 patients, comprising of individual having luminal disease while 25 percent having fistulising...

  • First oral therapies for multiple sclerosis anticipated. Hughes, Bethan // Nature Reviews Drug Discovery;Nov2009, Vol. 8 Issue 11, p831 

    The article assesses the efficacy of several oral drugs in development for the treatment of relapsing-remitting multiple sclerosis. Cladribine and fingolimod have shown good efficacy. Alemtuzumab, a humanized monoclonal antibody, offers key advantages in terms of convenience to patients. Side...

  • Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. Oliver, Begoña; Fernández, Óscar; Órpez, Teresa; Alvarenga, Marcos Papais; Pinto-Medel, María Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández, Victoria; Leyva, Laura // Multiple Sclerosis Journal;03/01/2011, Vol. 17 Issue 3, p368 

    Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing—remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that may affect the efficacy and safety of the drug. In this...

  • Sarcoidosis complicating treatment with natalizumab for Crohn's disease. Parisinos, C. A.; Lees, C. W.; Wallace, W. A. H.; Satsangi, J. // Thorax;Dec2011, Vol. 66 Issue 12, p1109 

    Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had...

  • Daclizumab in active relapsing multiple sclerosis (CHOI CE study): a Phase 2, randomised, double-blind, placebocontrolled, add-on trial with interferon beta.  // Current Medical Literature: Multiple Sclerosis;2010, Vol. 2 Issue 3, p80 

    In this article the author discusses the study on the placebo-controlled daclizumab in active relapsing multiple sclerosis (MS) with interferon beta. It states that daclizumab is a humanized monoclonal antibody in patients with MS while receiving standard disease-modifying therapy. The authors...

  • Progressive Multifocal Leukoencephalopathy and Newer Biological Agents. Berger, J. R. // Drug Safety;2010, Vol. 33 Issue 11, p969 

    Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the brain due to a polyoma virus, JC virus. Despite the ubiquity of this virus, PML is rare and almost always seen in association with an underlying immunosuppressive condition. In the last 30 years, AIDS has...


Read the Article


Sign out of this library

Other Topics